Beligas PharmaLGD-4033 10 Mg
| Quantity | Discount | Price |
|---|---|---|
| 3–5 | 10% | $108,00 |
| 6–9 | 15% | $102,00 |
| 10–100 | 20% | $96,00 |
Specifications
- Brand: Beligas Pharma HGH, Peptides & SARMs
- Substance: LGD-4033
- Product Form: Oral
- Dosage: 10 Mg
How To Use
Laboratory Administration & Research Dosing Protocols
Disclaimer: The following information is for educational and laboratory reference only. This product is strictly for in-vitro and in-vivo research and is not intended for human consumption or therapeutic use.
This product contains 10mg of active LGD-4033 per analytical unit. Due to its high bioavailability and extended half-life (roughly 24 to 36 hours in models), daily or every-other-day administration is standard.
Measurement Reference
- Half-Life: ~24-36 hours (allows for single daily dosing in models).
- Bioavailability: High systemic absorption via oral/sublingual or precise laboratory delivery methods.
Storage Specifications
- Storage: Store at controlled room temperature (20°C to 25°C), away from direct sunlight, moisture, and extreme heat to prevent chemical degradation of the active compound.
Experience Level Usage Guide
Beginner
Protocol A: Baseline Muscle Preservation Model
Reference dosing for studies investigating the prevention of muscle wasting during caloric deficits or mild cachexia.
- Test Subject Dosage: 2.5mg to 5.0mg daily.
- Administration: Systemic delivery.
- Observation Period: 6 to 8 weeks.
Intermediate
Protocol B: Active Hypertrophy & Osteoblast Stimulation Model
Standard clinical dosage for evaluating rapid lean mass accretion and significant increases in bone density.
- Test Subject Dosage: 10.0mg daily.
- Administration: Systemic delivery (administered consistently at the same time daily to maintain stable serum levels).
- Observation Period: 8 weeks.
Advanced
Protocol C: Advanced Tissue Regeneration & Synergistic Model
Advanced protocol for research involving severe musculoskeletal trauma or extreme hypertrophy models.
- Test Subject Dosage: 15.0mg to 20.0mg daily.
- Synergy: Often researched alongside MK-677 (Ibutamoren) to observe the synergistic effects of SARM-induced muscle synthesis combined with elevated IGF-1 levels.
- Observation Parameter: Strict monitoring of lipid panels and profound HPTA suppression is mandatory at this tier. Requires a full endocrine reset (PCT) post-observation.
Shipping Details
Detailed Description
What Is Beligas Pharma LGD-4033 10 mg?
Beligas Pharma LGD-4033 10 mg (commonly known as Ligandrol) is a highly potent, non-steroidal Selective Androgen Receptor Modulator (SARM). Engineered to provide the anabolic benefits of traditional androgens without the associated systemic side effects, LGD-4033 is designed to bind specifically to androgen receptors located in muscle and bone tissue, largely bypassing the prostate and sebaceous glands.
This 10 mg oral format manufactured by Beligas Pharma provides researchers with a highly stable, precisely dosed compound for conducting in vivo animal studies focused on muscle wasting diseases, osteoporosis and severe structural degradation.
Please note: This compound is strictly formulated for laboratory research and is not intended for human consumption, therapeutic use, or dietary supplementation.
| Technical Specification | Details |
|---|---|
| Compound Name | LGD-4033 (Ligandrol) |
| Format | 10 mg Oral Presentation |
| Purity Level | >99% (HPLC Verified) |
| Primary Research Area | Selective Muscle Hypertrophy & Bone Density |
Observed Benefits of LGD-4033 in Research Models
In controlled experimental environments, LGD-4033 has demonstrated exceptional anabolic activity with a high degree of tissue selectivity. Key observations in animal models include:
- Profound Muscular Hypertrophy: Rapidly increases nitrogen retention and protein synthesis, resulting in significant dose-dependent increases in lean muscle mass.
- Bone Mineralization: Research indicates a strong binding affinity to skeletal receptors, enhancing bone mineral density and acting as a primary marker for osteoporosis research.
- Prevention of Cachexia: Highly effective in reversing the effects of severe muscle-wasting conditions induced by metabolic stress or age in laboratory models.
- Favorable Safety Profile: Displays a high anabolic-to-androgenic ratio, minimizing the enlargement of the prostate or aggressive behavioral changes typically seen with traditional exogenous androgens.
Mechanism of Action
LGD-4033 operates through highly selective, high-affinity binding to the androgen receptor (AR). Unlike exogenous testosterone or steroidal derivatives that impact all ARs throughout the body (including those in the prostate, skin, and hair follicles), LGD-4033 features tissue-selective activation. Upon binding to receptors in skeletal muscle and bone, it alters the conformation of the receptor, initiating a cascade of genetic transcriptions that rapidly upregulate structural protein synthesis and bone matrix reinforcement.
Comparison: SARM Research Compounds
| Research Compound | Primary Focus | Comparison to LGD-4033 |
|---|---|---|
| Ostarine (MK-2866) | Joint Repair & Mild Anabolism | Ostarine is generally utilized for milder studies focusing on joint healing and maintaining baseline muscle. LGD-4033 is significantly more potent for driving sheer mass. |
| RAD-140 (Testolone) | Neurological & Strength Models | RAD-140 features higher androgenic signaling and neuroprotective properties, whereas LGD-4033 is the premier choice strictly for volumetric muscle hypertrophy. |
| LGD-4033 | Maximum Tissue Hypertrophy | The most biologically active non-steroidal SARM currently available for researching total lean mass accrual. |
Potential Side Effects of LGD-4033
In prolonged or high-dose animal testing, toxicological assessments note that while LGD-4033 avoids traditional steroidal side effects (such as severe hepatotoxicity or extreme prostate enlargement), it does cause a dose-dependent suppression of endogenous testosterone, Luteinizing Hormone (LH), and Follicle-Stimulating Hormone (FSH). Additionally, researchers often observe temporary shifts in lipid profiles (lowered HDL) during the active research phase.
Where to Buy Beligas Pharma LGD-4033 10 mg Online
When conducting complex SARM assays, the chemical purity of your compound dictates the validity of your data. Peptidesline supplies verified, laboratory-grade Beligas Pharma LGD-4033 10 mg directly from our secure inventory.
- Rapid US Logistics: Shipped directly from our USA facility, ensuring delivery in 4-7 business days.
- Secure Transactions: Checkout smoothly with Zelle or Venmo for laboratory privacy.
- Crypto Discount: Unlock an instant 10% discount on your entire order by paying with Bitcoin, Ethereum, USDT, or Litecoin.
- Click here for Payment Options
FAQ
No. Beligas Pharma LGD-4033 is supplied exclusively for in vitro laboratory research and in vivo animal studies. It is not approved for human medical use, bodybuilding, or dietary supplementation.
Traditional androgens bind non-selectively throughout the body, causing unwanted side effects like prostate growth. LGD-4033 is highly tissue-selective, binding almost exclusively to muscle and bone receptors to induce targeted hypertrophy.
Yes. Laboratory data confirms that LGD-4033, particularly in higher doses, causes dose-dependent suppression of natural testosterone and LH levels in animal models, requiring researchers to implement Post Cycle Therapy (PCT) protocols to restore endocrine function.
To ensure maximum precision, adding 2 ml of bacteriostatic water or solvent is recommended. On this peptide scale, 0.1 ml (10 units) on an insulin syringe provides 500 mcg (0.5 mg). At Peptidesline.com, we find this ratio helps users accurately test the 1.0 mg daily dose used in foundational clinical trials to assess lean body mass changes.
No. LGD-4033 is a SARM (Selective Androgen Receptor Modulator). While it produces anabolic (growth-promoting) effects similar to steroids, its chemical structure is entirely different. It targets muscle and bone receptors specifically, avoiding the severe organ toxicity associated with traditional steroids.
Yes. Despite its selectivity, LGD-4033 is highly suppressive to natural endocrine function at research doses (especially 10mg and above). Researchers must implement a PCT protocol (such as Kisspeptin-10 or standard SERMs) to restore the subject's natural HPTA axis following the observation period.
Because LGD-4033 does not aromatize into estrogen, it does not directly cause extracellular water retention (edema) in the same manner as testosterone. The mass gained during testing protocols is typically highly concentrated, dry muscle tissue.
